Atrial Fibrillation
Conditions
Keywords
Atrial fibrillation, spironolactone
Brief summary
To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.
Detailed description
To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.
Interventions
DRUGSpironolactone
25 mg po qd 25 mg po bid
DRUGPlacebo
Spironolactone 25 mg po qd
Sponsors
Taichung Veterans General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. 18 to 80 Y/O, 2. Paroxysmal AF.
Exclusion criteria
1. GPT\>100 IU/L or tota bilirubin \>2 mg/dl; 2. Creatinine \> 2 mg/dl; 3. Serum potassium \>= 5 mM; 4. Serum sodium \<=130 mM; 5. Uric acid \> 10 mg/dl。
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to a first electrocardiographically confirmed AF | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| 1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups. | 3 months |
Countries
Taiwan
Contacts
Primary ContactTsu-Juey Wu, M.D.
Outcome results
None listed